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Background: Intraperitoneal chemotherapy is used to treat peritoneal cancer. The pattern of gene expression
changes of peritoneal cancer during intraperitoneal chemotherapy has not been studied before. Pressurized
intraperitoneal aerosol chemotherapy is a new form of intraperitoneal chemotherapy using repeated applications
and allowing repeated tumor sampling during chemotherapy. Here, we present the analysis of gene expression
changes during pressurized intraperitoneal aerosol chemotherapy with doxorubicin and cisplatin using a 22-gene
panel.
Methods: Total RNA was extracted from 152 PC samples obtained from 63 patients in up to six cycles of
intraperitoneal chemotherapy. Quantitative real-time PCR was used to determine the gene expression levels. For
select genes, immunohistochemistry was used to verify gene expression changes observed on the transcript level
on the protein level. Observed (changes in) expression levels were correlated with clinical outcomes.
Results: Gene expression profiles differed significantly between peritoneal cancer and non- peritoneal cancer
samples and between ascites-producing and non ascites-producing peritoneal cancers. Changes of gene expression
patterns during repeated intraperitoneal chemotherapy cycles were prognostic of overall survival, suggesting a
molecular tumor response of peritoneal cancer. Specifically, downregulation of the whole gene panel during
intraperitoneal chemotherapy was associated with better treatment response and survival.
Conclusions: In summary, molecular changes of peritoneal cancer during pressurized intraperitoneal aerosol
chemotherapy can be documented and may be used to refine individual treatment and prognostic estimations.
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Peritoneal carcinomatosis (PC) can occur in the form of
primary peritoneal cancer or as a manifestation of a
number of different malignancies such as ovarian, fallo-
pian, colon, appendiceal, cholangiocellular, and gastric
cancer [1, 2]. Irrespective of the source of origin, PC is
difficult to treat and survival of affected patients is poor
with a median duration of overall survival of 6–15
months [3–5]. Local and regional treatment strategies
such as peritonectomy, peritonectomy combined with
hyperthermic intraperitoneal chemoperfusion (HIPEC),
and various modalities of intraperitoneal chemotherapy
(IPC), including pressurized intraperitoneal aerosol
chemotherapy (PIPAC), have been reported to achieve ob-
jective treatment responses in patients with PC of various
origins [6–9]. In view of the poor prognosis of patients
with PC, a better understanding of the molecular biology
of this disease and the identification of new predictive and
prognostic markers is an unmet medical need.
In patients with PC, distinct gene expression patterns
of PC tumor cells have been associated with therapy re-
sponse and prognosis. For example, Verhaak et al. used a
100 gene signature including RB1, NFKBIB, and RXRB
for molecular subtyping of advanced ovarian cancer
specimens with peritoneal metastases [10]. Others have
used gene expression patterns to characterize the mo-
lecular pathway highlighting the transition of primary
ovarian tumors to peritoneal metastases. For example,
Brodsky et al. found that PC cells originating from ovar-
ian cancer were more proliferative and less apoptotic
than their respective primary tumors. In addition, peri-
toneal metastases had copy number aberrations that
differed from those found in the primary tumor: a six
gene expression signature including EFTUD1, CALB2,
TIMP3, CYP1B1, IL7R, and RARRES2 distinguished pri-
mary from metastatic tumors and predicted overall sur-
vival [11]. In a similar study of 47 epithelial ovarian
cancers, microarray analysis using an Affymetrix plat-
form identified a 56 gene set with differential expression
discriminating the primary tumor from peritoneal me-
tastases [12]. Of note, 10/56 genes were involved in the
p53 gene pathway. Matte et al. studied gene expression
changes in human peritoneal mesothelial cells (HPMCs)
exposed to malignant ascites from ovarian cancer with
PC [13]. In this study, a total of 649 genes were differen-
tially expressed in ascites-stimulated HPMCs with 484
genes up-regulated and 165 genes down-regulated. Thus,
we felt it is reasonable to investigate whether tumor
samples with contact to ascites would have different
gene expression patterns compared to tumor samples
without such exposure.
In summary, gene expression patterns in malignancies
with PC such as ovarian cancer have prognostic and pre-
dictive value, discriminate between primary tumor andPC metastases, and react specifically to malignant asci-
tes. A number of genes and gene pathways, e.g. p53,
Akt, NF-kB, and VEGF seem to play a critical role in the
development and sustained growth of PC. However, the
pattern of gene expression changes of PC during chemo-
therapy has not been studied before. Whether or not
gene expression changes of PC during chemotherapy
have any prognostic or predictive value, is unknown.
Here, we present the results of gene expression analyses of
a panel of 22 genes in tissue samples obtained during re-
peated cycles of PIPAC in patients with PC originating
from ovarian cancer. To our knowledge, this is the first
study to investigate gene expression patterns during re-
peated applications of chemotherapy in patients with PC.
Methods
Patient samples
This is a retrospective analysis of samples and clinical
data obtained during 152 IPC procedures performed
between March 2013 and June 2014 in 63 women with
PC. Patient and sample characteristics are described in
Tables 1 and 2, respectively. Prior to study inclusion, all
patients had undergone at least two lines of standard
intravenous chemotherapy. PIPAC was used as IPC
treatment and was performed as described previously
[14–17]. At the beginning of each procedure, the Peri-
toneal Cancer Index (PCI) was determined according to
Sugarbaker, based on lesion size and distribution [18].
Prior to the application of chemotherapy (cisplatin at a
dose of 7.5 mg/m2 body surface in 150 ml 0.9 %-NaCl
solution followed by doxorubicin at a dose of 1.5 mg/m2
body surface in 50 ml 0.9 %-NaCl solution; see [15]),
peritoneal biopsies were taken both for conventional
histological analysis and for gene expression testing. The
laboratory team was blinded to the clinical outcome. If
present, ascites was removed at the same time and asci-
tes volume was documented. PIPAC and PC sampling
was repeated every 4 to 6 weeks until progression, death,
or unacceptable toxicity. Patients were followed-up until
January 2015 or death. Median follow-up was 158 days
(range: 9–640 days; interquartile range: 75–310 days).
RNA isolation and cDNA synthesis
Total RNA was isolated from snap-frozen tissue samples
using the RNeasy Mini RNA isolation kit (Qiagen,
Hilden, Germany) following the instructions of the
manufacturer. In brief, up to 30 mg of tissue were
weighed out in 2-ml-reaction tubes, covered with lysis
buffer (RLT, provided with the kit, supplemented with
1 % β-mercaptoethanol), and disrupted/homogenized
using a rotor-stator homogenizer (TissueRuptor, Qiagen).
The homogenate was applied to the RNeasy spin columns,
washed, and finally eluted in water. RNA was quantified
using a BioPhotometer (Eppendorf, Hamburg, Germany).
Table 1 Patient characteristics of 63 women with peritoneal
cancer undergoing repeated pressurized intraperitoneal aerosol
chemotherapy (PIPAC) with cisplatin and doxorubicin
Patient characteristic Value
Number of patients 63
Age (years; mean ± SD) 62.0 ± 11.3
Previous chemotherapy regimens (median, range) 3 (2–8)
Presence of ascites 35/63 (56.6 %)
Ascites volume (ml; median, range) 150 (10–4500)
PCI (mean ± SD) 17.5 ± 10.0
Serum CA125 (U/ml; mean ± SD) 1590 ± 3753
Primary tumor
Ovarian cancer 58 (92.1 %)
Endometrial cancer 3 (4.7 %)
Pseudomyxoma peritonei 1 (1.6 %)
Stomach cancer 1 (1.6 %)
Cell type
Serous papillary adenocarcinoma 37/63 (58.7 %)
Mucinous adenocarcinoma 2/63 (3.2 %)
Other 24/63 (38.1 %)
Number of patients sampled at PIPAC 1 and
at least one follow-up PIPAC (2, 3, or 4)
42
Number of patients sampled at PIPAC 1, 2 and 3 28
SD standard deviation, PCI Peritoneal Cancer Index
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cDNA Synthesis Kit (Life Technologies/Thermo Fisher
Scientific) after treatment with RNase-free DNase I (Life
Technologies) to eliminate contamination with genomic
DNA. Typical yields were (0.56 ± 0.54) μg total RNA per
1 mg tissue (median 0.26, range 0.02–2.41). RNA quality
was routinely checked by agarose gel electrophoresis and
assessing the integrity of the 28S and 18S rRNA bands.
Gene panel
In this study, we examined a 22 gene panel (see Additional
file 1: Table S1). Specific genes were chosen based on
previous literature associating these genes with ovarianTable 2 Sample characteristics
Sample characteristic Value
Total number of analyzed samples 152
Obtained during PIPAC 1 (“untreated”) 53 (34.9 %)
Obtained during PIPAC ≥2 (“treated”) 99 (65.1 %)
Histologically assessed as
Tumor 136 (89.5 %)
With concurrent ascites 88 (64.7 %)
Without concurrent ascites 48 (35.3 %)
Tumor-free 16 (10.5 %)cancer carcinogenesis and metastatic promotion [10–13, 19].
A list of corresponding primers, primer sequences, prod-
uct lengths, and GenBank accession numbers can be
found in Additional file 2: Table S2.
Quantitative real-time PCR
PCR was performed using the Maxima SYBR Green/ROX
qPCR Master Mix (Life Technologies) in an ABI 7900HT
Fast Real-Time PCR System (Applied Biosystems) in
384-well plates (BIOplastics, Landgraaf, The Netherlands).
Reactions (10 μl total volume) consisted of 5 μl 2x Master
Mix, 2 μl cDNA, 3 μl primer mix (final primer concentra-
tion was 0.3 μM). A two-step cycling protocol was used:
10 min initial denaturation (95 °C) and 40 cycles of 15 s
denaturation (95 °C) and 60 s annealing/extension (60 °C).
All reactions were carried out in triplicates. Absence of
contaminating genomic DNA was confirmed by amp-
lifying cDNA and corresponding amounts of RNA
with GAPDH and ACTB primers. Primers were ei-
ther designed using Primer3 [20] or taken from
https://primerdepot.nci.nih.gov. All primers were manu-
ally checked against their targets’ GenBank entries and
wherever possible, it was made sure that the PCR prod-
ucts spanned exon-exon boundaries. Each product was
verified by agarose gel electrophoresis (not shown) and
expected melting temperature (OligoCalc) [21]. Specific
amplification of products was routinely checked by melt-
ing curve analysis after each run. Transcription of 1 μg
RNA into cDNA and 100-fold dilution (final) for real-time
PCR resulted in cycle threshold (Ct) values of 22.3 ± 3.8
and 23.2 ± 3.7 for the reference genes ACTB and GAPDH,
respectively. The difference between the Ct values of the
reference genes was 0.9 ± 1.4. Thus, for sample-to-sample
comparison of gene expression, the ΔΔCt-method was
employed using the mean Ct of both reference genes.
Immunohistochemistry
Immunohistochemical analysis was performed as de-
scribed before [22]. The material was routinely fixed in
4 % formaldehyde solution and embedded in paraffin.
After slicing into 4-μm-thick sections, the preparations
were dewaxed in xylene and then rehydrated. Endogen-
ous peroxidase activity was blocked by 3 % hydrogen
peroxide in methanol for 30 min. After a short rinse
with phosphate buffered saline (PBS), sections were
pre-incubated with avidin-biotin (Vector Laboratories,
Peterborough, UK; SP-2001) for 15 min to reduce
non-specific background staining. The preparations
were covered with normal goat serum for 20 min and
then incubated with the primary antibodies (CD44,
mouse monoclonal, Diagnostic Biosystems, Pleasanton,
CA, dilution 1:2000; CD44v6, abcam, Cambridge, MA, di-
lution 1:1000; and VEGF, mouse monoclonal, Dako,
Denmark, dilution 1:50) for 30 min. Then, the sections
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anti-mouse immunoglobulin G (BioGenex, Germany) for
30 min and covered with peroxidase-conjugated streptavi-
din (Dako). The peroxidase reaction was allowed to
proceed for 8 min, with 0.05 % 3,3-diaminobenzidine tet-
rahydrochloride solution as substrate. Slides were counter-
stained with hematoxylin. Negative controls were also
performed by replacing the primary antibodies with
mouse or goat ascites fluid (Sigma-Aldrich, St. Louis,
MO).
Data analysis and statistics
Amplification data were analyzed using the SDS 2.4.1
and RQ Manager 1.2.1 software packages (Applied Bio-
systems). Clinical data and gene expression data were
entered and further processed in Microsoft Excel 2013.
Statistical analyses and data visualization was carried out
using SigmaPlot 12.5 (Systat Software, San Jose, CA).
Gene expression data from our sample collective rarely
followed a normal distribution. Thus, non-parametric
tests were used. To compare gene expression between
groups of samples (such as those in Figs. 1 and 2), the
Mann–Whitney U (Wilcoxon) rank sum test was used.
For the analysis gene expression changes in specimens
drawn from the same individuals over multiple sam-
plings, the following statistical tests were used: Wilcoxon
signed rank test, Friedman’s repeated measures analysis
of variance (ANOVA) on ranks (Tukey test for pairwise
multiple comparisons; in case of normal distribution of
the data, one way repeated measures ANOVA was used
with the Holm-Sidak method for pairwise multiple com-
parisons), and two way repeated measures ANOVA (to
test for interaction with other variables). The statistical
significance of survival curve differences was assessedFig. 1 Comparison of mRNA expression levels of a panel of genes between
b assessed as tumor with concomitant presence of ascites vs. no ascites; an
IPC within the first PIPAC procedures (pre, untreated). In each case, the sam
The magnitude of the mean expression level ratios of the groups is indicat
darkest gray). Arrowheads indicate whether the expression is higher (up) o
higher/lower are indicated at the far right. Statistical significance of differen
by asterisks (***, p < 0.001; **, p < 0.01; *, p < 0.05). A color version of the figusing the Kaplan-Meier log rank analysis. To assess haz-
ard ratios, the Cox proportional hazards model was
employed.
Results
Molecular markers differentiate PC tumor tissue from
normal peritoneum
Peritoneal biopsies were taken during each PIPAC cycle
immediately prior to the application of chemotherapy. In
16 of 152 peritoneal biopsies, no tumor tissue was
identified in the histological examination. These tissue
samples served as non-tumor controls representing
undiseased peritoneum. Tumor and non-tumor samples
differed significantly in the expression of 10/22 genes
(Fig. 1a): CCNB1, CLDN4, CLDN6, MMP2, MUC1 (all:
p < 0.05), BAG1, SERPINB3 (all: p < 0.01), CD44 (stand-
ard variant), MKI67, and MYBL2 (all: p < 0.001). As ex-
pected, the tumor sample population showed higher
expression levels of pro-mitotic genes such as CCNB1
and MYBL2, genes that modulate the host immune
response, such as SERPINB3, and the tight-junctions
proteins claudin-4 and claudin-6, which are often
deregulated in cancers. CD44 isoforms were also found
to be deregulated as observed in many types of cancer.
Interestingly, the anti-apoptotic gene BAG1 appeared to
be slightly diminished (less than 2-fold) in the tumor
sample population.
Ascites-producing tumors have a distinct gene expression
profile
We expected that ascites-producing PC differs from non
ascites-producing PC on the molecular level and that
this difference would potentially be reflected in our gene
panel. Indeed, when comparing tumor samples from PCgroups of a samples histologically assessed as tumor vs. tumor-free;
d c obtained after initial IPC (post, treated) vs. initial sampling before
ples were taken before the application of the chemotherapy aerosol.
ed by different levels of gray (from <1.5-fold, lightest gray to >8-fold,
r lower (down) in the first group. The numbers of genes expressed
ces between the groups (Mann–Whitney rank sum test) is indicated







Fig. 2 Predictive value of gene expression profiles. Patients were grouped into responders and non-responders judged by histological evaluation
of tissue samples (regression; a), serum levels of CA125 (decline; b), PCI (improved; c) or volume of ascites (reduction; d). Panel e shows patients
grouped as high (response in ≥2 categories) and low responders (response in <2 categories). Corresponding samples obtained before the first
IPC and histologically confirmed as tumors were analyzed. The magnitude of the mean expression level ratios of the groups is indicated by
different levels of gray (from <1.5-fold, lightest gray to >8-fold, darkest gray). Arrowheads indicate whether the expression is higher (up) or lower
(down) in the respective response group (or high responders in E, respectively). The numbers of genes expressed higher/lower are indicated at
the far right. Statistical significance of differences between the groups (Mann–Whitney rank sum test) is indicated by asterisks (*, p < 0.05).
Panel f shows overall survival of high and low responders (Kaplan-Meier log rank analysis). A color version of the figure is available in Additional file 8
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35.3 %), 10/22 genes showed significantly different ex-
pression levels (Fig. 1b). BAG1, CLDN6, SERPINB3 (all:
p < 0.05), BIRC5, CCNB1, MYBL2 (all: p < 0.01), and
MMP11 and MUC1 (all: p < 0.001) were expressed at
higher, and CLDN4 (p < 0.05) and MMP9 (p < 0.01) were
expressed at lower levels in samples from patients with
ascites.
Samples from IPC-treated patients show an overall lower
expression of the gene panel
Next, we compared the average gene expression levels in
samples from patients who had undergone at least one
IPC treatment round (“post”; obtained during second or
later PIPAC procedure) to those in samples from IPC-
naïve patients (“pre”; obtained during the first PIPAC
procedure). We observed an overall lower expression in
18/22 genes (Fig. 1c), although with rare and only weak
statistical significance.
Gene expression profiles prior to IPC and prediction of
treatment response
In order to identify predictive molecular markers for
treatment response, we compared the gene expression
profiles in sample sets obtained during the first PIPAC
procedure (i.e. IPC-naïve) from patients classified as re-
sponders or non-responders in four response categories.
Response to PIPAC treatment was measured by a) histo-
logic regression, b) decline of serum CA125 levels, c)
improved PCI, and d) reduction of ascites volume, in
each case comparing the status before the initial PIPAC
with that at PIPAC 3 (or in few cases, earlier for patients
who could not continue treatment cycles due to sideeffects or death). We found that gene expression patterns
before the start of chemotherapy were not predictive of
any of these four response categories (Fig. 2a-d). Gene ex-
pression patterns were comparable in pre-IPC tumor sam-
ples with or without subsequent clinical response. The
same was true when the samples obtained prior to the first
PIPAC treatment were stratified based on a composite of
response criteria (low responders = response in <2 of the
four categories described above versus high responders =
response in ≥2 categories) (Fig. 2e). That the response cri-
teria are clinically valid and correspond to the oncological
outcome was demonstrated by a significantly diminished
overall survival of the low responders (p = 0.033) with a
hazard ratio (HR) of 2.37 (95 % confidence interval [CI]
1.05–5.38; p = 0.037).
Differential gene expression during IPCs predicts
treatment response and survival
To assess the effect of PIPAC treatment on individual
patients, we looked at gene expression changes over the
course of up to six PIPAC treatments. Additional file 3:
Figure S1 shows “spaghetti plots” for all 22 genes in our
gene panel. Expression patterns of individual genes in
our patient sample are quite heterogeneous. Some vary
only moderately (at most approx. 4-fold) across patients
and time points (e.g. BAG1, MMP2, VIM), others are
very heterogeneously expressed, both in magnitude and
over time (e.g. CLDN4 and 6, MUC1 and 4, SERPINB3).
To further analyze the expression data longitudinally,
we encoded the expression change of each gene for all
patients where samples at different time points were
available (N = 44; in all cases the tumor of origin was
ovarian cancer) as a heat map (Fig. 3a). Expression
Fig. 3 (See legend on next page.)
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Fig. 3 Heat map of gene expression changes in patient samples throughout IPC cycles a and of IPC-induced overall gene expression change b
and in subset of high c and low response patients d judged by clinical response categories. a Each row represents a patient for whom an IPC-naïve
tumor sample and at least one sample from PIPAC cycles 2 or 3 was available (n = 44), and each column corresponds to a specific gene. Patients (rows)
were grouped according to treatment response as judged by histologic regression, decline of serum CA125 levels, improved PCI, and reduction of
ascites volume as indicated in the columns to the left of the heat map (Y = response, N = no response, − = not applicable/data missing). b Statistical
significance of expression change for individual genes was assessed by the Wilcoxon signed rank test, Friedman ANOVA on ranks (or one way [1*]
ANOVA in case of normally distributed data; note that only data from a subset of 28 patients was considered; see text), and two way (2*) ANOVA using
high/low clinical responders as additional factor. c, d Expression changes in samples of high and low responders and statistical significance assessed
by the Holm-Sidak method of multiple pairwise comparison within the two way ANOVA described in B. a-d The magnitude of expression change is
reflected by different levels of gray intensity (see legends); arrowheads indicate whether gene expression goes up or down in the course of IPC. The
numbers of up-/downregulated genes are indicated at the far right. Statistical significance is indicated by asterisks (***, p < 0.001; **, p < 0.01; *,
p < 0.05). A color version of the figure is available in Additional file 9
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the initial treatment (N = 42), to the expression levels in
the sample obtained during the third PIPAC procedure
(N = 31), or when this sample was not available from
those during the fourth (N = 1) or second (N = 10)
PIPAC procedure; additionally, two cases were included
where only samples from the second and third PIPAC
procedure were available, but not from the initial pro-
cedure (N = 2). In Fig. 3a, patients (each row corre-
sponds to an individual patient) are grouped by clinical
response (as detailed in the columns to the left of the
heat map). Of note, when looking at (the color version
of ) Fig. 3a, treatment response appears to be associated
with general downregulation of the whole gene panel
induced by the treatment. In the low response group
(response in <2 categories), ≥1.5-fold upregulation or
downregulation occurred in 107 and 114 analyses,
respectively. In contrast, ≥1.5-fold upregulation or
downregulation in the high response groups (response
in ≥2 categories) occurred in 175 and 308 analyses,
respectively (p = 0.003; two-tailed, Fisher’s exact test).
A more sophisticated statistical analysis of these data
is shown in Fig. 3b–d. Figure 3b shows the average ex-
pression level changes induced by IPC and demonstrates
that treatment leads to an overall downregulation of the
whole gene panel. Using a cutoff of at least 1.5-fold
change in expression level, 18/22 genes were found
downregulated and none upregulated. The differences in
expression before and after treatment were statistically
significant (Wilcoxon signed rank test) in case of CCNB1,
PAK1 (both: p < 0.01), CCNE1, CLDN4, CLDN6, CTSL2,
MUC1, MUC4, and VEGF (all: p < 0.05). Repeating this
analysis on a subset of cases (N = 28) where three
consecutive samples (PIPAC 1, 2, and 3) were available,
Friedman repeated measures ANOVA on ranks (one way
repeated measures ANOVA in select cases where data
followed a normal distribution), CCNB1, MUC1, PAK1,
and VEGF downregulation was confirmed as statistically
significant, and additionally revealing an upregulation of
VIM (p < 0.01) in this subset of patients. In all cases, a sta-
tistically significant difference was present between theinitial sample (“untreated”) and that obtained during the
third PIPAC (i.e. having undergone two rounds of IPC).
In addition, a statistically significant interaction be-
tween treatment induced change of gene expression and
response judged by clinical response categories was
found for MYBL2 (p < 0.01), CD44s, CLDN6, TOP2A,
and VIM (all: p < 0.05). In the subgroup of high re-
sponders (Fig. 3c), statistically significant downregulation
of CLDN6 (p < 0.001) and MYBL2 (p < 0.01) was found,
while VIM was upregulated (p < 0.01). In the low re-
sponse group (Fig. 3d), no significant differences were
present and the effect of overall IPC-induced downregu-
lation of the gene panel was lost.
We hypothesized that the degree of IPC-induced up-
and downregulation of the whole 22-gene panel can
serve as a predictor of patient outcome on par or better
than the clinical response categories histology, CA125,
PCI and/or ascites. To test this hypothesis, we calculated
a “gene panel score” for each patient (N = 44) from the
data shown in Fig. 3a. The score was calculated as a
weighted sum across the genes, downregulation count-
ing as positive, upregulation as negative. The weighting
factors for changes <1.5-fold and changes ≥1.5, 2, 4, 8,
16, and 32-fold in gene expression were 0, 0.5, 1, 2, 3, 4,
and 5, respectively. The overall survival of the 44 pa-
tients included in this analysis, grouped as low and high
responders, is shown in Fig. 4a. Note that the survival
curves for both groups are similar to those for the super-
set of 61 patients shown in Fig. 2f, but their difference is
not quite statistically significant (p = 0.066; Cox regres-
sion: HR = 2.5, 95 %CI 0.9–6.8, p = 0.075). When defin-
ing a cutoff of zero for the score, and thus comparing
overall survival between patients with a score ≥0 to
those with a score <0, survival of the latter group is sig-
nificantly diminished (p = 0.012; Cox regression: HR =
3.4, 95 %CI 1.2–9.5, p = 0.018) (Fig. 4b). Thus, the gene
panel score appears superior to our combination of clin-
ical response categories. A graphical representation of
the differential gene expression data in the patients ac-
cording to gene panel score is shown in Fig. 4c. To ar-
rive at this figure, the heat map shown in Fig. 3a has
Fig. 4 Prognostic value of gene panel expression changes induced by IPC. Overall survival of patients stratified as high and low responders a is
juxtaposed to that of patients with a gene panel score≥ 0 or < 0 b. The heat map shown in Fig. 3a has been reformatted c. Each row represents
a patient (n = 44) with individual genes sorted from greatest downregulation (left) to greatest upregulation (right); the magnitude of gene
expression change is indicated (from <1.5-fold, white, to >32-fold, darkest). Rows are sorted by gene panel score, highest (top) to lowest (bottom).
A color version of the figure is available in Additional file 10
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bottom with decreasing gene panel score, and within rows
by sorting by magnitude of gene expression change, great-
est downregulation (left) to greatest upregulation (right).
Additional file 4: Figure S2 shows Kaplan-Meier log
rank analysis of patient overall survival (N = 42) grouped
by ≥1.5-fold upregulation, ≥1.5-fold downregulation, or
<1.5-fold change for each of the 22 genes in the gene
panel. Statistically significant differences in survival were
identified for BAG1 (no change vs. downregulation) and
CLDN6 (up- vs. downregulation), both at p < 0.05.
Immunohistochemistry validated results obtained on the
mRNA level
In a subset of PC tumor samples selected based on large
difference in expression level on the mRNA level, we an-
alyzed the protein expression of CD44, CD44v6, and
VEGF by immunohistochemistry (based on established
in-house methods and availability of antibodies). Semi-
quantitative analysis of CD44, CD44v6, and VEGF expres-
sion confirmed expression changes during intraperitoneal
chemotherapy, i.e. gain or loss of protein expression.
Additional file 5: Figure S3 demonstrates loss/gain of
CD44, CD44v6, and VEGF expression when compar-
ing samples taken before the first IPC and samples
taken during subsequent PIPAC procedures.
Discussion
In the present study we found that molecular markers
differentiate between PC tumor tissue and tumor-free
peritoneum as well as between ascites-producing and
non ascites-producing PC. PC samples taken prior toPIPAC had no predictive value, but gene expression
changes during repeated IPC were associated with clin-
ical treatment response. A molecular subtype character-
ized by overall downregulation of the whole gene panel
predicted overall patient survival. Thus, the analysis of
consecutive PC tumor samples obtained during repeated
cycles of PIPAC allowed us to document response of PC
to IPC on the molecular level and to correlate these
findings with response parameters and clinical outcome.
One of the main finding of this study is that the ex-
pression changes of the 22 gene panel are associated
with disease outcome. Specifically, when we looked at
the interaction between clinical responses (such as histo-
logic regression, improved PCI, declining CA125 serum
levels, and reduced ascites production) and molecular
response, we observed an even more pronounced overall
downregulation of the gene panel (with the exception of
VIM) in patients showing clinical improvement versus
those who did not. In the first group, three genes
showed statistically significant changes: CLDN6 and
MYBL2 (both downregulated) and VIM (upregulated),
whereas CLDN6 and VIM were downregulated and up-
regulated, respectively, in the latter group.
MYBL2 was specifically downregulated in the high
response group. Ren et al. reported that, in colorectal can-
cer, MYBL2 was significantly overexpressed and inversely
correlated with disease-free survival [23]. It has further
been described as a putative biomarker found upregulated
in cervical cancer [24]. While the role of MYBL2 in ovarian
cancer and derived entities is not well established, our data
would indicate that it acts similarly in PC of ovarian cancer
origin. In line with this is that MYBL2 is located on a
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chromosomal clustering of genes displaying altered
expression patterns in ovarian cancer [25].
New prognostic markers for patients with PC are
needed to refine therapy and prognosis estimation in
this precarious patient group. Consistent with previous
studies, clinical and histopathological features such as
histologic regression, decline of serum CA125 levels, im-
proved PCI, and reduction of ascites volume during the
course of IPC were associated with prognosis [15, 26].
Here, we demonstrate that our gene panel and the score
derived from its expression level changes throughout re-
peated IPC treatments represents a prognostic marker
that is superior to clinical and histopathological features
described above, individually or in combination. It
is, however, a limitation of our study that we used
a pre-selected gene panel instead of a whole gen-
ome expression analysis. Thus, we cannot rule out
that the positive findings in this study only repre-
sent a subset of relevant genes, which are differen-
tially regulated by IPC (and potentially specifically
by PIPAC). Further studies using whole genome
analyses and larger sample sets may expand our
preliminary findings.
As expected, we found that gene expression patterns
are different in PC tumor samples compared to normal,
undiseased peritoneum with a number of genes differen-
tially regulated: BAG1, CCNB1, CD44, CLDN4 and 6,
MMP2, MKI67, MUC1, MYBL2, and SERPINB3. Given
the properties of their protein products, this finding is
consistent with the hypothesis that malignant trans-
formation of peritoneum into PC is associated with de-
regulation of three mechanisms [27]: (a) growth and
proliferation via BAG1, CCNB1, MKI67, and MYBL2,
(b) cell adhesion and forced migration via CD44 stand-
ard, MUC1, CLDN4, and CLDN6, followed by in-
creased local invasiveness through upregulation of
MMP2, and (c) VEGF-mediated angiogenesis. Deregu-
lation of the expression of BAG1, CCNB1, MKI67, and
MYBL2 was documented in PC biopsies, suggesting
that growth and cell proliferation pathways are dis-
turbed, a feature of malignant transformation in ovarian
and peritoneal cancer that has been widely documented
in the literature [10–13, 19, 27]. Loss of cell adhesion
via deregulation of CD44, CLDN4, and CLDN6, followed
by increased migration and invasive capabilities through
upregulation of MMP2 describes a pattern consistent with
localized ovarian cancer cells transforming into metasta-
sizing PC cells, and expands previous data showing that
deregulation of proliferation and cell adhesion is a feature
of malignant transformation in ovarian and peritoneal
cancer [10–13, 19, 28]. Tjhay et al., for instance, have
shown that disseminated ovarian tumors in the periton-
eum contain highly enriched CD44v6-positive cancer cellsand an increased number of CD44v6-positive cancer cells
in primary tumors was associated with a shortened overall
survival in stage III-IV ovarian cancer [29]. In a xenograft
model, Haria et al. found that DLX4, a transcription factor
encoded by a homeobox gene, induced expression of
CD44 in ovarian tumor cells, and inhibition of CD44
abrogated the ability of DLX4 to stimulate tumor-
mesothelial cell interactions [30]. The fact that CD44
drives inflammatory signaling in PC is also consistent with
our finding of differential regulation of SERPINB3,
associated with host-immune-response [31]. Further-
more, strong expression of SERPINB3 protein was
characterized as a prognostic factor for platinum re-
sistance and for poor progression-free survival [32],
providing an alternative or additional explanation for
the increased expression of SERPINB3 in our patients
who all had undergone several systemic chemother-
apies before recruitment for PIPAC.
Besides gene expression differences between PC sam-
ples and tumor-free peritoneum, we also found that
ascites-producing PC has a distinct gene expression pro-
file compared to non-ascites producing PC. Specifically,
10/22 genes were differently expressed, namely BAG1,
BIRC5, CCNB1, CLDN4 and 6, MMP9 and 11, MUC1,
MYBL2, and SERPINB3. This finding of a gene signature
for ascites-producing PC is consistent with previous data
analyzing differences in gene expression between PC
with miliary and non-miliary peritoneal spread [33]. In
this study, Auer et al. analyzed tumor tissues and ascites
from 23 chemotherapy-naive patients by RNA-sequencing
and flow cytometry. Pathway analysis of the differentially
expressed genes in ascites yielded 11 deregulated pathways
including MMP9 as deregulated key player. This is con-
sistent with our finding of MMP9 being deregulated in
ascites-producing PC.
As for inclusion criteria, only patients who had
undergone previous platinum-containing chemother-
apy were treated with PIPAC. Thus, all patients can
be considered platinum-resistant. The reason for
using cisplatin as one of the intraabdominal drugs is
that the chemotherapy concentration is significantly
higher after local application than after systemic ap-
plication and may thus overcome platinum resistance
by local drug escalation.
Conclusion
In summary, we documented a molecular response to
IPC in PC tumor samples obtained during repeated con-
secutive cycles of PIPAC with cisplatin and doxorubicin.
These changes correlated with clinical outcome and
could be used to predict overall survival. Thus, measur-
ing gene expression changes during the time window of
treatment may be useful for refining individual treat-
ment and prognosis estimations.
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